secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2026-08-13T20:00:18+00:00
Accession:  0001193125-26-349107
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Q2 net loss $65.6M; DAYBREAK topline due Sept 2026, cash into 2027
-------------------------------------------------------------------------

- Q2 2026 net loss $65.6M ($1.05/sh) vs $54.3M ($1.03/sh) in Q2 2025; SBC $11.6M.
- Cash and equivalents $125.9M at June 30, 2026; expected to fund operations into 2027.
- R&D expense $56.1M (up from $42.8M) on PEAK/PINNACLE and manufacturing; G&A $10.8M.
- Phase 3 DAYBREAK topline (Zenkuda/KSI-501, wet AMD) expected Sept 2026; PEAK Pivotal Analysis 1 (KSI-101, MESI) Dec 2026.
- Enrollment completed for first 300-patient PEAK cohort; ALTO Phase 3 (KSI-501 vs aflibercept, DME) patient enrollment initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/0001193125-26-349107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer